Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer
Conditions
Breast Neoplasms
Conditions: official terms
Breast Neoplasms
Conditions: Keywords
exemestane, aspirin, quality of life
Study Type
Interventional
Study Phase
Phase 2
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Intervention
Name: aspirin Type: Drug
Name: Exemestane Type: Drug
Overall Status
Recruiting
Summary
This is a phase II study to assess efficacy/safety of Exemestane with or without Aspirin as the adjuvant treatment in postmenopausal breast cancer patients.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 80 Years
Minimum Age: 50 Years
Gender: Female
Criteria: Inclusion Criteria:

- Breast cancer after surgery postmenopausal

Exclusion Criteria:

- contraindication of aspirin
Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, China
Status: Recruiting
Contact: Peng Yuan, M.D. - 86-135 0127 0834 - yuanpeng01@hotmail.com
Start Date
July 2011
Completion Date
July 2014
Sponsors
Chinese Academy of Medical Sciences
Source
Chinese Academy of Medical Sciences
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page